Pfleiderer - comment

With a background from the University of Chicago and A&M, Donald Fetherstone carries my personal sympathy. But bringing in an outside, professional CRO to adapt the business to more frugal times and bring Silekol back into the "House of Pain" sounds like the right medicine to us. We wish him success.